{
  "resultsSection": {
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "Patients who do not withdraw consent will be followed for survival after end of treatment on a monthly to bi-monthly basis or until death, whichever occurs first. Patients removed from study for unacceptable adverse events will be followed for life every 6 months, unless they withdraw consent.",
      "description": "Arm D and Arm E did not enrolled any patients",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF",
          "description": "VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.\n\nbortezomib (Velcade): 1.3 mg/m2 IVP on days 1, 4, 8 and 11\n\ncyclophosphamide: 2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)\n\nG-CSF: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 20,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 20,
          "otherNumAffected": 8,
          "otherNumAtRisk": 20
        },
        {
          "id": "EG001",
          "title": "Arm B: VELCADE & G-CSF",
          "description": "VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection\n\nbortezomib (Velcade): 1.3 mg/m2 IVP on days 1, 4, 8 and 11\n\nG-CSF: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 4,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 4,
          "otherNumAffected": 4,
          "otherNumAtRisk": 4
        }
      ]
    }
  }
}